Singapore markets closed

ABBV Dec 2025 155.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
27.770.00 (0.00%)
As of 03:35PM EDT. Market open.
Full screen
Previous close27.77
Open27.77
Bid0.00
Ask0.00
Strike155.00
Expiry date2025-12-19
Day's range27.77 - 27.77
Contract rangeN/A
Volume1
Open interestN/A
  • Insider Monkey

    12 Best Dividend Stocks with High Upside Potential

    In this article, we discuss 12 best dividend stocks with high upside potential. You can skip our detailed analysis of dividend stocks and their past performance, and go directly to read 5 Best Dividend Stocks with High Upside Potential. The current state of the US economy is uncertain with many analysts gravitating toward the idea […]

  • Benzinga

    What's Going On AbbVie Stock On Friday?

    Friday, AbbVie Inc (NYSE:ABBV) released an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The shares are trading lower with a session volume of 3.9 million versus the average volume of 5.6 million, as per the data from Benzinga Pro. Also Read: AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue an

  • PR Newswire

    AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

    AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcome